PCV70 Examining Medication Adherence and Low Density Lipoprotein- Cholesterol (LDL-C) Goals among Tricare Beneficiaries Receiving Statin Therapy for Secondary Prevention of Coronary Heart Disease in US Military Treatment Facilities  by Nwokeji, E. et al.
A$4942 (95% CI $3509 to $6375) more in mean total costs compared to cerebro-
vascular (CerVD) patients respectively. A history of atrial fibrillation (AF), PAD and
diabeteswas associatedwith higher resource utilization.CONCLUSIONS:Our anal-
ysis has found that significant predictors of resource utilization and medical costs
were PAD, AF, and diabetes. The results highlight the need for policies that target
reducing the number of co-morbidities, which will decrease the incidence of PAD,
AF and diabetes in population, given current and projected burden. This data pro-
vide the necessary framework for economic evaluations of health interventions.
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OBJECTIVES: There are few large trials devoted to atrial fibrillation (AF) manage-
ment in the acute care setting, and no standardized strategy in place. METHODS:
RHYTHM-AF is a prospective observational study fielded in 10 countries. Patients
considered for cardioversion (electrical, ECV or pharmacological, PCV) were en-
rolled betweenMay 2010 and April 2011 (n 3397). We comparedmedical resource
(MR) and median lengths of stay (LoS) calculated as discharge minus admission
time. RESULTS: Patients’ serum haemoglobin and creatinine were measured most
frequently in Spain (99.4% and 99.0%) and least in the Netherlands (49.7% and
96.7%). Thyroid hormone levels were most often available in Germany (78.6%) and
least in Spain (7.3%). Italy, France, Poland and UK performed transthoracic echo-
cardiography commonly (55.5%, 67.7%, 72.1% and 70.4% respectively). Transoe-
sophageal echocardiography was rarely administered, except in Germany (73.1%).
Chest X-ray also varied from 95.2% (Spain) to 8.9% (Sweden). LoS varied by region
andmode of CV. Australia (66% ECV), the Netherlands (77 %), Sweden (96%) and UK
(85%) had LoS  24 hrs. Among those whose primary mode of cardioversion was
ECV, the LoS was highest in Poland (51% ECV) at a median of 54 hours, in Germany
(91%) at 53 hours and in France (81%) at 46 hrs. Among those on PCV, France (20%)
and Australia (35%) had the highest LoS at 192 and 140 hrs, respectively; the Neth-
erlands (23%) and Spain (79%) the lowest, at 5 and 10 hrs. CONCLUSIONS: There is
regional variability in MR and LoS among AF patients. Several patient-, physician-
,and/or environmental- level factors may contribute to this variation. Further re-
search examining factors which may contribute to and result from extensive hos-
pital stays and diagnostic procedures and to assess whether the variability of these
are associatedwith one another iswarranted to further inform clinical practice and
quality of care.
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OBJECTIVES: To examine how cost sharing for prescription drugs affects compli-
ance with antiplatelet therapy and subsequent health outcomes among patients
with acute coronary syndrome (ACS). METHODS: A retrospective outcomes study
using administrative data from medical and pharmaceutical claims of patients
enrolled at health plans offered by 26 large employers drawn from all regions of the
country. A total of 14,325 patients were diagnosed as having ACS and underwent
coronary stent implantation between 2002 and 2005. Each patient was followed up
for a maximum of 2 years. Primary outcomes measures were adoption of outpa-
tient antiplatelet therapy, adherence to outpatient therapy, hospital admissions,
and healthcare expenditures. RESULTS: Patients with ACS who face higher coin-
surance are less likely to adopt outpatient antiplatelet therapy within the first
month after stent implantation and aremore likely to discontinue treatment in the
first year after stent implantation (P 0.01). Higher coinsurance is also associated
with an increased number of ACS rehospitalizations (P 0.01). For patients in
health plans with higher coinsurance rates, expected costs from ACS hospitaliza-
tions are $2796 (38%) higher in the first year after stent implantation (P 0.01).
CONCLUSIONS: Higher copayments for prescription drugs are associated with
lower utilization of antiplatelet therapy and with higher likelihood of rehospital-
ization among patients with ACS. As a consequence, total healthcare spending for
patients with ACS increases by approximately $615 in the first year after stent
implantation.
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OBJECTIVES: Dysphagia is a frequent complication occurring after stroke as a con-
sequence of neurologic lesions at stake in controlling swallowing reflexes. Unman-
aged dysphagia has been associated with an increased risk of aspiration pneumo-
nia and evenmortality. Alongsidemorbi-mortality, dysphagia has also been shown
to increase inpatient length of stay. This often leads to incremental inpatient costs
of care directly or through its complications. This study aimed at gathering unit
costs related to dysphagia for stroke patients. METHODS: A combined literature
and expert-based costing study was carried out for the following dysphagia cost
items: screening, severity staging, rehabilitation and pulmonary complications.
These costs were primarily estimated based on medical fees and technical proce-
dures billing. 2011 US unit costs and charges according to Medicare perspective
were estimated. RESULTS: Early bedside screening and Speech Language Patholo-
gist (SLP) based clinical assessment ranged between USD 16-26 and USD 40-105
respectively. Instrumental severity staging by either Videofluoroscopy, or Fiberop-
tic Endoscopic Evaluation (with sensory testing or not) was estimated to fall be-
tween USD 331-348. Swallowing disorder rehabilitative sessionmediated by an SLP
is charged aroundUSD 94. Inpatient costs related to aspiration pneumonia second-
ary to post-stroke dysphagia were estimated to range between USD 19,509 - 22,714.
CONCLUSIONS: This study demonstrated the potential economic benefits of any
intervention aiming at reducing the risk of aspiration when considering the high
costs of associated pneumonia.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes & Patient
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OBJECTIVES:The objective of this studywas to determine the prevalence of patient
behavioral segments and medication adherence levels by segment for a hyperten-
sive patient population. METHODS: Members from MediGuard.org and other on-
line patient panels in the UK, Germany, Italy, and Spain were invited to participate
in aweb-based survey that included: a patient segmentation instrument developed
by CoMac Analytics based on a linguistic analysis of patient talk and the MARS-5
adherence instrument. Subjects were screened to have a diagnosis of hypertension
and treatment with at least one anti-hypertensive agent. RESULTS: 353 patients
completed the on-line survey in August/September 2011 and were categorized
against three different behavioral domains: control orientation [176 (50%)
Iinternal, 177 (50%) Eexternal], emotion [100 (28%) Ppositive, 253 (72%)
Nnegative], and agency or ability to act on choices [227 (64%) Hhigh agency, 126
(36%) Llow agency]. Domains were grouped into 8 different clusters with EPH and
IPH arising as the most common (88 respondents (25%) in each cluster). The prev-
alence of other behavior clusters ranged from 6% (22 respondents, INH) to 12% (41
respondents, IPL). The proportion of patients defined as adherent (scored 25 on
MARS-5) varied sharply across the segments: 51% adherent (45 of 88 respondents)
for the IPH vs. 8% adherent (2 of 25 respondents) classified as INL. Side effects, being
employed, and stopping medicine because the patient got better were all signifi-
cant determinants of adherence in a probit regression model. CONCLUSIONS: By
categorizing patients into worldview segments, we identified wide differences in
adherence that can be used to prioritize interventions and to customize adherence
messages.
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OBJECTIVES: To examine statin adherence and LDL-C targeted treatment goals
(TTGs) among TRICARE beneficiaries receiving treatment for secondary prevention
of coronary heart disease (CHD) at US Military Treatment Facilities (MTFs).
METHODS: Retrospective cohort database study examining TRICARE beneficiaries
18-75 years of age, receiving medical services for a primary CHD event at an MTF
between Jan-1-2004 and Dec-31-2008. Of the 20,658 MTF patients receiving statin-
therapy for CHD, 3,676 had an LDL-C value recorded during subsequent 6-month
(M6), 12-month (M12) and 18-month (M18) periods. TTGswere defined usingATPIII-
NCEP Guidelines (i.e., LDL-C value100mg/dL). Drug adherence was measured us-
ing the Medication Possession Ratio (MPR) at M6,M12, and M18. Persistence was
measured as time to 35-day refill gap. Covariates included age, gender, benefi-
ciary status, comorbidities, statin switching, dosage titrations and other lipid low-
ering therapies. Logistic and Cox regressions were conducted to assess predictors
of TTG and adherence/persistence. RESULTS:The CHD cohortwas 75%male,mean
age 58.8 (SD9.3) years. The percent of patients adherent (MPR0.80) with statin-
therapy was 85% at M6, 79% at M12, and 78% at M18. Older diabetic patients were
more adherent and at TTG. Adjusting for covariates, adherent patients were more
likely to be at TTG in M6,M12, and M18 (OR1.98[1.62-2.42], 2.69[2.25-3.22], and
2.93[2.44-3.52], respectively). Overall mean persistence to statins was 330 (SD199)
days. Approximately 68% of patients were persistent at M6, 50% at M12, and 37% at
M18. Patients at TTGwere less likely to experience a gap in therapy at M6,M12, and
M18 (HR0.83[0.78-0.89],0.80[0.76-0.84], and 0.80[0.77-0.84]). CONCLUSIONS: This
study showed a positive link between statin adherence andTTGs among secondary
prevention patients with frequent LDL-C monitoring in the MHS. Patients with
better adherence to statin-therapy were more likely to be at TTG, compared to
non-adherent patients. Further study is needed to assess generalizability to all
MHS secondary prevention patients.
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